- 理想的成長型公司, 本業EPS的成長幅度會大於營收的成長幅度
- 營收到某個數字後, 本業EPS呈現不成比例的增加, 有可能是規模經濟的效應
- 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
- 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
- 如果EPS衰退，要觀察同業是不是有一樣的狀況
- 要留意增資減資和公司債對股本及EPS的影響
| 加權平均股數 QoQ YoY | EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | 營收 QoQ YoY | 毛利率(%) QoQ YoY | 營業利益率 QoQ YoY | 稅後淨利率 QoQ YoY | 營業利益 QoQ YoY | 稅後淨利 QoQ YoY | 稅前淨利率(%) QoQ YoY | 稅後淨利率(%) QoQ YoY | 兩季平均(YOY)營收成長率(%) | 兩季平均(YOY)EPS成長率(%) | 兩季平均(YOY)本業EPS成長率(%) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 102 | 0.99 | 0.99 | 14.15 | 21.88 | 94.37 | 9.29 | 135.19 | -7.93 | 32.87 | 75.96 | 33.46 | 56.15 | 11.7 | 82.6 | 42.32 | 9.04 | -20.84 | 21.68 | 46.78 | -45.31 | 25.90 | 7.29 | 6.94 | 12.17 | 63.8 | -0.16 | 14.47 | 23.46 | 97.41 | 30.57 | 1.66 | 1.87 | 25.90 | 7.29 | 6.94 | 43.83 | 43.04 | 49.81 |
| 24Q2 (19) | 101 | 0.0 | 31.17 | 11.61 | 64.21 | 29.72 | 3.95 | -35.56 | -60.5 | 18.68 | 164.21 | -17.13 | 50.27 | 75.95 | 60.15 | 38.81 | -26.36 | -29.37 | 14.77 | -52.69 | -65.58 | 24.14 | -7.23 | 8.11 | 7.43 | -16.7 | -44.84 | 11.72 | 63.69 | 69.36 | 30.07 | -12.64 | -7.39 | 24.14 | -7.23 | 8.11 | 32.53 | 44.78 | -37.19 |
| 24Q1 (18) | 101 | 1.0 | 32.89 | 7.07 | 25.35 | -48.09 | 6.13 | -38.82 | -45.37 | 7.07 | -76.59 | -48.09 | 28.57 | -10.89 | -40.24 | 52.70 | -0.43 | 30.83 | 31.22 | -11.88 | -3.55 | 26.02 | 43.05 | 19.25 | 8.92 | -21.48 | -42.34 | 7.16 | 26.5 | -31.09 | 34.42 | 62.36 | 14.09 | 26.02 | 43.05 | 19.25 | -3.32 | 1.41 | -19.75 |
| 23Q4 (17) | 100 | -0.99 | 33.33 | 5.64 | -22.53 | 5.03 | 10.02 | -0.69 | 63.19 | 30.20 | 22.61 | 63.07 | 32.06 | 4.26 | -39.49 | 52.93 | -0.99 | 156.57 | 35.43 | -10.62 | 185.27 | 18.19 | -24.9 | 136.23 | 11.36 | -6.81 | 72.64 | 5.66 | -22.78 | 40.1 | 21.20 | -29.36 | 157.59 | 18.19 | -24.9 | 136.23 | 1.11 | -20.59 | 0.11 |
| 23Q3 (16) | 101 | 31.17 | 34.67 | 7.28 | -18.66 | -3.96 | 10.09 | 0.9 | 139.1 | 24.63 | 9.27 | 87.3 | 30.75 | -2.04 | 12.89 | 53.46 | -2.71 | 61.46 | 39.64 | -7.62 | 67.82 | 24.22 | 8.46 | 14.9 | 12.19 | -9.5 | 89.58 | 7.33 | 5.92 | 28.82 | 30.01 | -7.58 | 4.53 | 24.22 | 8.46 | 14.9 | -18.19 | -26.48 | -4.98 |
| 23Q2 (15) | 77 | 1.32 | 13.24 | 8.95 | -34.29 | 154.26 | 10.00 | -10.87 | 325.53 | 22.54 | 65.49 | 267.7 | 31.39 | -34.34 | 131.66 | 54.95 | 36.42 | 40.93 | 42.91 | 32.56 | 57.35 | 22.33 | 2.34 | 26.02 | 13.47 | -12.93 | 265.04 | 6.92 | -33.4 | 188.33 | 32.47 | 7.62 | 19.2 | 22.33 | 2.34 | 26.02 | -22.05 | 59.67 | 35.93 |
| 23Q1 (14) | 76 | 1.33 | 11.76 | 13.62 | 153.63 | 419.85 | 11.22 | 82.74 | 541.14 | 13.62 | -26.46 | 419.85 | 47.81 | -9.76 | 328.02 | 40.28 | 95.25 | 15.55 | 32.37 | 160.63 | 43.74 | 21.82 | 183.38 | 36.03 | 15.47 | 135.11 | 513.89 | 10.39 | 157.18 | 480.45 | 30.17 | 266.59 | 33.2 | 21.82 | 183.38 | 36.03 | 42.36 | 62.23 | 64.12 |
| 22Q4 (13) | 75 | 0.0 | 10.29 | 5.37 | -29.16 | 160.68 | 6.14 | 45.5 | 335.46 | 18.52 | 40.84 | 67.75 | 52.98 | 94.49 | 360.7 | 20.63 | -37.69 | -36.72 | 12.42 | -47.42 | -23.33 | 7.70 | -63.47 | -36.78 | 6.58 | 2.33 | 253.76 | 4.04 | -29.0 | 188.57 | 8.23 | -71.33 | -48.11 | 7.70 | -63.47 | -36.78 | 97.76 | 43.09 | 62.53 |
| 22Q3 (12) | 75 | 10.29 | 10.29 | 7.58 | 115.34 | 275.25 | 4.22 | 79.57 | 189.04 | 13.15 | 114.52 | 45.95 | 27.24 | 101.03 | 129.1 | 33.11 | -15.08 | 10.62 | 23.62 | -13.38 | 29.5 | 21.08 | 18.96 | 82.04 | 6.43 | 74.25 | 196.31 | 5.69 | 137.08 | 312.32 | 28.71 | 5.4 | 65.76 | 21.08 | 18.96 | 82.04 | 61.17 | 74.84 | 56.93 |
| 22Q2 (11) | 68 | 0.0 | 25.93 | 3.52 | 34.35 | 38.58 | 2.35 | 34.29 | 62.07 | 6.13 | 133.97 | -29.7 | 13.55 | 21.31 | 13.48 | 38.99 | 11.85 | 37.1 | 27.27 | 21.09 | 68.65 | 17.72 | 10.47 | 53.82 | 3.69 | 46.43 | 91.19 | 2.4 | 34.08 | 73.91 | 27.24 | 20.26 | 77.92 | 17.72 | 10.47 | 53.82 | 9.22 | 30.77 | 29.20 |
| 22Q1 (10) | 68 | 0.0 | 25.93 | 2.62 | 27.18 | -57.61 | 1.75 | 24.11 | -46.15 | 2.62 | -76.27 | -57.61 | 11.17 | -2.87 | -18.29 | 34.86 | 6.93 | -20.77 | 22.52 | 39.01 | -31.55 | 16.04 | 31.69 | -34.42 | 2.52 | 35.48 | -44.0 | 1.79 | 27.86 | -46.41 | 22.65 | 42.81 | -31.63 | 16.04 | 31.69 | -34.42 | -3.08 | 14.58 | 10.34 |
| 21Q4 (9) | 68 | 0.0 | 25.93 | 2.06 | 1.98 | -74.57 | 1.41 | -3.42 | 220.45 | 11.04 | 22.53 | 2.6 | 11.5 | -3.28 | 72.16 | 32.60 | 8.92 | -25.07 | 16.20 | -11.18 | 113.44 | 12.18 | 5.18 | -81.32 | 1.86 | -14.29 | 264.71 | 1.4 | 1.45 | -67.82 | 15.86 | -8.43 | -75.96 | 12.18 | 5.18 | -81.32 | -1.85 | -9.24 | -1.36 |
| 21Q3 (8) | 68 | 25.93 | 61.9 | 2.02 | -20.47 | 51.88 | 1.46 | 0.69 | 124.62 | 9.01 | 3.33 | 159.65 | 11.89 | -0.42 | 199.5 | 29.93 | 5.24 | -21.91 | 18.24 | 12.8 | 0.05 | 11.58 | 0.52 | -16.69 | 2.17 | 12.44 | 201.39 | 1.38 | 0.0 | 150.91 | 17.32 | 13.13 | 12.91 | 11.58 | 0.52 | -16.69 | -6.54 | -39.69 | -27.35 |
| 21Q2 (7) | 54 | 0.0 | 28.57 | 2.54 | -58.9 | 144.23 | 1.45 | -55.38 | 173.58 | 8.72 | 41.1 | 307.48 | 11.94 | -12.66 | 229.83 | 28.44 | -35.36 | -21.63 | 16.17 | -50.85 | 0.43 | 11.52 | -52.9 | -3.84 | 1.93 | -57.11 | 232.76 | 1.38 | -58.68 | 220.93 | 15.31 | -53.79 | 17.05 | 11.52 | -52.9 | -3.84 | 45.99 | -41.30 | 291.63 |
| 21Q1 (6) | 54 | 0.0 | 31.71 | 6.18 | -23.7 | 461.82 | 3.25 | 638.64 | 692.68 | 6.18 | -42.57 | 461.82 | 13.67 | 104.64 | 266.49 | 44.00 | 1.13 | 26.36 | 32.90 | 333.47 | 174.17 | 24.46 | -62.49 | 105.03 | 4.5 | 782.35 | 900.0 | 3.34 | -23.22 | 659.09 | 33.13 | -49.78 | 164.62 | 24.46 | -62.49 | 105.03 | 86.45 | 242.66 | 303.16 |
| 20Q4 (5) | 54 | 28.57 | 38.46 | 8.10 | 509.02 | 548.0 | 0.44 | -32.31 | -24.14 | 10.76 | 210.09 | 36.2 | 6.68 | 68.26 | 70.84 | 43.51 | 13.51 | 14.47 | 7.59 | -58.37 | -40.47 | 65.21 | 369.14 | 428.87 | 0.51 | -29.17 | 2.0 | 4.35 | 690.91 | 806.25 | 65.97 | 330.05 | 557.07 | 65.21 | 369.14 | 428.87 | - | - | 0.00 |
| 20Q3 (4) | 42 | 0.0 | 0.0 | 1.33 | 27.88 | 0.0 | 0.65 | 22.64 | 0.0 | 3.47 | 62.15 | 0.0 | 3.97 | 9.67 | 0.0 | 38.33 | 5.62 | 0.0 | 18.23 | 13.23 | 0.0 | 13.90 | 16.03 | 0.0 | 0.72 | 24.14 | 0.0 | 0.55 | 27.91 | 0.0 | 15.34 | 17.28 | 0.0 | 13.90 | 16.03 | 0.0 | - | - | 0.00 |
| 20Q2 (3) | 42 | 2.44 | 0.0 | 1.04 | -5.45 | 0.0 | 0.53 | 29.27 | 0.0 | 2.14 | 94.55 | 0.0 | 3.62 | -2.95 | 0.0 | 36.29 | 4.22 | 0.0 | 16.10 | 34.17 | 0.0 | 11.98 | 0.42 | 0.0 | 0.58 | 28.89 | 0.0 | 0.43 | -2.27 | 0.0 | 13.08 | 4.47 | 0.0 | 11.98 | 0.42 | 0.0 | - | - | 0.00 |
| 20Q1 (2) | 41 | 5.13 | 0.0 | 1.10 | -12.0 | 0.0 | 0.41 | -29.31 | 0.0 | 1.10 | -86.08 | 0.0 | 3.73 | -4.6 | 0.0 | 34.82 | -8.39 | 0.0 | 12.00 | -5.88 | 0.0 | 11.93 | -3.24 | 0.0 | 0.45 | -10.0 | 0.0 | 0.44 | -8.33 | 0.0 | 12.52 | 24.7 | 0.0 | 11.93 | -3.24 | 0.0 | - | - | 0.00 |
| 19Q4 (1) | 39 | 0.0 | 0.0 | 1.25 | 0.0 | 0.0 | 0.58 | 0.0 | 0.0 | 7.90 | 0.0 | 0.0 | 3.91 | 0.0 | 0.0 | 38.01 | 0.0 | 0.0 | 12.75 | 0.0 | 0.0 | 12.33 | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.48 | 0.0 | 0.0 | 10.04 | 0.0 | 0.0 | 12.33 | 0.0 | 0.0 | - | - | 0.00 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 20.89 | 3.23 | 85.94 | 155.89 | 28.63 | 59.83 | N/A | 113.04起合併子公司USL營收及113.08.20收購Emergent BioSolutions旗下位於美國馬里蘭康登鎮無菌製劑廠營收納入合併 | ||
| 2024/9 | 20.24 | 8.22 | 99.24 | 135.0 | 22.78 | 56.15 | 0.97 | 113.04起合併子公司USL營收及113.08.20收購Emergent BioSolutions旗下位於美國馬里蘭康登鎮無菌製劑廠營收納入合併 | ||
| 2024/8 | 18.7 | 8.67 | 88.55 | 114.76 | 15.0 | 52.88 | 1.03 | 113.04起合併子公司USL營收及113.08.20收購Emergent BioSolutions旗下位於美國馬里蘭康登鎮無菌製劑廠營收納入合併 | ||
| 2024/7 | 17.21 | 1.42 | 61.14 | 96.06 | 6.88 | 51.06 | 1.06 | 113.04起合併子公司Upsher-Smith Laboratories營收 | ||
| 2024/6 | 16.97 | 0.5 | 48.48 | 78.85 | -0.43 | 50.27 | 0.99 | - | ||
| 2024/5 | 16.88 | 2.77 | 55.75 | 61.88 | -8.68 | 40.83 | 1.22 | 113.04起合併子公司Upsher-Smith Laboratories營收 | ||
| 2024/4 | 16.43 | 118.25 | 80.08 | 45.0 | -20.94 | 32.75 | 1.52 | 113.04起合併子公司Upsher-Smith Laboratories營收 | ||
| 2024/3 | 7.53 | -14.45 | -42.53 | 28.57 | -40.22 | 28.57 | 0.83 | - | ||
| 2024/2 | 8.8 | -28.18 | -44.14 | 21.05 | -39.35 | 30.55 | 0.78 | - | ||
| 2024/1 | 12.25 | 28.91 | -35.37 | 12.25 | -35.37 | 33.02 | 0.72 | - | ||
| 2023/12 | 9.5 | -15.64 | -43.4 | 141.95 | 35.26 | 32.01 | 0.67 | 12月單月減少原因:子公司安成藥業11204起調整產品架構 | ||
| 2023/11 | 11.27 | 0.26 | -32.47 | 132.45 | 50.25 | 32.66 | 0.66 | 11月單月減少原因:子公司安成藥業11204起調整產品架構 | ||
| 2023/10 | 11.24 | 10.57 | -42.81 | 121.19 | 69.54 | 31.32 | 0.69 | 10月單月減少原因:子公司安成藥業11204起調整產品架構 | ||
| 2023/9 | 10.16 | 2.45 | -43.69 | 109.95 | 111.6 | 30.76 | 0.75 | 111.09起合併子公司安成國際藥業營收 | ||
| 2023/8 | 9.92 | -7.12 | 111.3 | 99.79 | 195.42 | 32.02 | 0.72 | 111.09起合併子公司安成國際藥業營收 | ||
| 2023/7 | 10.68 | -6.54 | 143.91 | 89.87 | 209.0 | 32.94 | 0.7 | 111.09起合併子公司安成國際藥業營收 | ||
| 2023/6 | 11.43 | 5.42 | 185.0 | 79.19 | 220.54 | 31.38 | 0.63 | 111.09起合併子公司安成國際藥業營收 | ||
| 2023/5 | 10.84 | 18.82 | 115.98 | 67.76 | 227.42 | 33.06 | 0.6 | 111.09起合併子公司安成國際藥業營收 | ||
| 2023/4 | 9.12 | -30.35 | 103.02 | 56.93 | 263.09 | 37.97 | 0.52 | 111.09起合併子公司安成國際藥業營收 | ||
| 2023/3 | 13.1 | -16.86 | 220.88 | 47.81 | 327.88 | 47.81 | 0.38 | 111.09起合併子公司安成國際藥業營收 | ||
| 2023/2 | 15.75 | -16.89 | 376.92 | 34.71 | 389.47 | 51.37 | 0.35 | 111.09起合併子公司安成國際藥業營收 | ||
| 2023/1 | 18.96 | 13.74 | 400.41 | 18.96 | 400.41 | 52.31 | 0.34 | 111.09起合併子公司安成國際藥業營收 | ||
| 2022/12 | 16.67 | -0.11 | 358.18 | 104.82 | 113.91 | 53.0 | 0.37 | 111.09起合併子公司安成國際藥業營收 | ||
| 2022/11 | 16.68 | -15.09 | 341.72 | 88.15 | 94.05 | 54.38 | 0.36 | 111.09起合併子公司安成國際藥業營收 | ||
| 2022/10 | 19.65 | 8.87 | 381.52 | 71.48 | 71.62 | 42.39 | 0.46 | 111.09起合併子公司安成國際藥業營收 | ||
| 2022/9 | 18.05 | 284.53 | 308.65 | 51.83 | 37.95 | 27.12 | 0.86 | 111.09起合併子公司安成國際藥業營收 | ||
| 2022/8 | 4.69 | 7.21 | 15.94 | 33.78 | 1.88 | 13.08 | 1.78 | - | ||
| 2022/7 | 4.38 | 9.2 | 29.45 | 29.08 | -0.06 | 13.41 | 1.74 | - | ||
| 2022/6 | 4.01 | -20.1 | 9.44 | 24.71 | -3.94 | 13.52 | 0.78 | - | ||
| 2022/5 | 5.02 | 11.69 | 18.15 | 20.7 | -6.17 | 13.6 | 0.77 | - | ||
| 2022/4 | 4.49 | 9.72 | 8.5 | 15.68 | -11.97 | 11.89 | 0.89 | - | ||
| 2022/3 | 4.09 | 23.95 | -24.75 | 11.19 | -18.17 | 11.19 | 0.84 | - | ||
| 2022/2 | 3.3 | -12.8 | -16.46 | 7.09 | -13.83 | 10.73 | 0.88 | - | ||
| 2022/1 | 3.79 | 4.14 | -11.39 | 3.79 | -11.39 | 11.2 | 0.84 | - | ||
| 2021/12 | 3.64 | -3.7 | 1.97 | 49.06 | 174.08 | 11.5 | 0.8 | 109.12起合併加拿大子公司營收 | ||
| 2021/11 | 3.78 | -7.44 | 147.41 | 45.43 | 216.91 | 12.27 | 0.74 | 109.12起合併加拿大子公司營收 | ||
| 2021/10 | 4.08 | -7.6 | 174.24 | 41.65 | 225.19 | 12.55 | 0.73 | 109.12起合併加拿大子公司營收 | ||
| 2021/9 | 4.42 | 9.1 | 201.29 | 37.57 | 231.89 | 11.85 | 0.84 | 109.12起合併加拿大子公司營收 | ||
| 2021/8 | 4.05 | 19.7 | 206.44 | 33.15 | 236.44 | 11.09 | 0.9 | 109.12起合併加拿大子公司營收 | ||
| 2021/7 | 3.38 | -7.67 | 185.36 | 29.1 | 241.09 | 11.29 | 0.88 | 109.12起合併加拿大子公司營收 | ||
| 2021/6 | 3.66 | -13.74 | 182.52 | 25.72 | 250.08 | 12.05 | 0.81 | 109.12起合併加拿大子公司營收 | ||
| 2021/5 | 4.25 | 2.57 | 241.96 | 22.06 | 264.55 | 13.83 | 0.71 | 109.12起合併加拿大子公司營收 | ||
| 2021/4 | 4.14 | -23.9 | 282.33 | 17.81 | 270.37 | 13.54 | 0.72 | 109.12起合併加拿大子公司營收 | ||
| 2021/3 | 5.44 | 37.6 | 348.05 | 13.67 | 266.89 | 13.67 | 0.78 | 109.12起合併加拿大子公司營收 | ||
| 2021/2 | 3.95 | -7.5 | 235.69 | 8.23 | 227.64 | 11.8 | 0.9 | 109.12起合併加拿大子公司營收 | ||
| 2021/1 | 4.28 | 19.85 | 220.54 | 4.28 | 220.54 | 9.37 | 1.14 | 109.12起合併加拿大子公司營收 | ||
| 2020/12 | 3.57 | 133.63 | 146.69 | 17.9 | 17.05 | 6.58 | 1.65 | 109.12起合併加拿大子公司營收 | ||
| 2020/11 | 1.53 | 2.59 | 16.75 | 14.33 | 3.52 | 4.48 | 2.42 | - | ||
| 2020/10 | 1.49 | 1.5 | 28.52 | 12.81 | 2.14 | 4.28 | 2.54 | - | ||
| 2020/9 | 1.47 | 10.97 | 31.38 | 11.32 | -0.54 | 3.97 | 0.77 | - | ||
| 2020/8 | 1.32 | 11.46 | -22.1 | 9.85 | -4.01 | 3.8 | 0.8 | - | ||
| 2020/7 | 1.19 | -8.59 | 13.34 | 8.53 | -0.43 | 3.72 | 0.82 | - | ||
| 2020/6 | 1.3 | 4.39 | 9.82 | 7.35 | -2.35 | 3.62 | 0.79 | - | ||
| 2020/5 | 1.24 | 14.67 | -0.8 | 6.05 | -4.61 | 3.54 | 0.81 | - | ||
| 2020/4 | 1.08 | -10.82 | -14.97 | 4.81 | -5.54 | 3.48 | 0.82 | - | ||
| 2020/3 | 1.21 | 3.09 | -22.54 | 3.73 | -2.4 | 3.73 | 0.73 | - | ||
| 2020/2 | 1.18 | -11.67 | 23.97 | 2.51 | 11.63 | 3.96 | 0.69 | - | ||
| 2020/1 | 1.33 | -7.75 | 2.61 | 1.33 | 2.61 | 4.09 | 0.67 | - | ||
| 2019/12 | 1.45 | 10.57 | 26.92 | 15.29 | 11.42 | 0.0 | N/A | 107.03起合併益邦營收 | ||
| 2019/11 | 1.31 | 12.93 | 4.41 | 13.85 | 10.02 | 0.0 | N/A | 107.03起合併益邦營收 |
| 加權平均股數 YoY | EPS YoY | 本業EPS YoY | 營收 YoY | 毛利率(%) YoY | 營業利益率 YoY | 稅後淨利率 YoY | 營業利益 YoY | 稅前淨利 YoY | 稅後淨利 YoY | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 100 | 33.33 | 29.39 | 60.6 | 41.32 | 185.95 | 142.0 | 35.32 | 49.23 | 77.34 | 36.97 | 101.8 | 21.63 | 62.02 | 52.49 | 173.1 | 40.64 | 120.87 | 30.3 | 117.67 |
| 2022 (9) | 75 | 10.29 | 18.30 | 66.21 | 14.45 | 90.89 | 104.94 | 114.16 | 27.76 | -18.64 | 18.32 | -14.19 | 13.35 | -12.75 | 19.22 | 83.75 | 18.4 | 79.69 | 13.92 | 85.6 |
| 2021 (8) | 68 | 25.93 | 11.01 | 3.09 | 7.57 | 269.27 | 49.0 | 172.22 | 34.12 | -12.76 | 21.35 | 69.98 | 15.30 | -52.4 | 10.46 | 362.83 | 10.24 | 72.1 | 7.5 | 29.76 |
| 2020 (7) | 54 | 38.46 | 10.68 | 35.71 | 2.05 | -35.53 | 18.0 | 17.72 | 39.11 | -6.99 | 12.56 | -44.3 | 32.14 | 61.1 | 2.26 | -34.49 | 5.95 | 83.08 | 5.78 | 89.51 |
| 2019 (6) | 39 | 44.44 | 7.87 | -50.53 | 3.18 | 125.53 | 15.29 | 11.44 | 42.05 | 29.54 | 22.55 | 65.2 | 19.95 | -38.43 | 3.45 | 84.49 | 3.25 | -33.26 | 3.05 | -31.15 |
| 2018 (5) | 27 | 8.0 | 15.91 | 2741.07 | 1.41 | 840.0 | 13.72 | 283.24 | 32.46 | -7.81 | 13.65 | 162.5 | 32.40 | 655.24 | 1.87 | 884.21 | 4.87 | 2605.56 | 4.43 | 3064.29 |
| 2017 (4) | 25 | 8.7 | 0.56 | -46.67 | 0.15 | -44.44 | 3.58 | 26.5 | 35.21 | -16.19 | 5.20 | -51.81 | 4.29 | -50.52 | 0.19 | -38.71 | 0.18 | -35.71 | 0.14 | -44.0 |
| 2016 (3) | 23 | 4.55 | 1.05 | -30.0 | 0.27 | 50.0 | 2.83 | 18.91 | 42.01 | -1.06 | 10.79 | 35.38 | 8.67 | -38.77 | 0.31 | 63.16 | 0.28 | -20.0 | 0.25 | -26.47 |
| 2015 (2) | 22 | 0.0 | 1.50 | 94.81 | 0.18 | -18.18 | 2.38 | 9.17 | 42.46 | -4.15 | 7.97 | -32.17 | 14.16 | 85.83 | 0.19 | -26.92 | 0.35 | 75.0 | 0.34 | 100.0 |
| 2014 (1) | 22 | 37.5 | 0.77 | 220.83 | 0.22 | 340.0 | 2.18 | 134.41 | 44.30 | 0 | 11.75 | 0 | 7.62 | 0 | 0.26 | 1200.0 | 0.2 | 1900.0 | 0.17 | 325.0 |
